platelet aggregation inhibitors

Summary

Summary: Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Top Publications

  1. ncbi Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
    Jean Pierre Bassand
    Eur Heart J 28:1598-660. 2007
  2. ncbi Genetic determinants of response to clopidogrel and cardiovascular events
    Tabassome Simon
    Assistance Publique Hopitaux de Paris, Hopital Saint Antoine, and Universite Pierre et Marie Curie, Paris 06, France
    N Engl J Med 360:363-75. 2009
  3. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
  4. ncbi Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    Robert G Hart
    Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Ann Intern Med 146:857-67. 2007
  5. pmc Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
    Alan R Shuldiner
    Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, 660 W Redwood St, Room 494, Baltimore, MD 21201, USA
    JAMA 302:849-57. 2009
  6. ncbi Peripheral arterial disease detection, awareness, and treatment in primary care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    JAMA 286:1317-24. 2001
  7. ncbi Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
    Jonathan Mant
    Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
    Lancet 370:493-503. 2007
  8. ncbi Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    S Schulman
    Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 3:692-4. 2005
  9. pmc Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    JAMA 304:1821-30. 2010
  10. ncbi CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis
    Michael V Holmes
    Genetic Epidemiology Group, Department of Epidemiology and Public Health, University College London, 1 19 Torrington Pl, London, WC1E 6BT, United Kingdom
    JAMA 306:2704-14. 2011

Detail Information

Publications330 found, 100 shown here

  1. ncbi Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
    Jean Pierre Bassand
    Eur Heart J 28:1598-660. 2007
  2. ncbi Genetic determinants of response to clopidogrel and cardiovascular events
    Tabassome Simon
    Assistance Publique Hopitaux de Paris, Hopital Saint Antoine, and Universite Pierre et Marie Curie, Paris 06, France
    N Engl J Med 360:363-75. 2009
    ..The effect of these determinants on clinical outcomes after an acute myocardial infarction is unknown...
  3. ncbi Ticagrelor versus clopidogrel in patients with acute coronary syndromes
    Lars Wallentin
    Uppsala Clinical Research Center, Uppsala, Sweden
    N Engl J Med 361:1045-57. 2009
    ..Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel...
  4. ncbi Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation
    Robert G Hart
    Department of Medicine Neurology, University of Texas Health Science Center, San Antonio, Texas 78229 3900, USA
    Ann Intern Med 146:857-67. 2007
    ..Atrial fibrillation is a strong independent risk factor for stroke...
  5. pmc Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy
    Alan R Shuldiner
    Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, 660 W Redwood St, Room 494, Baltimore, MD 21201, USA
    JAMA 302:849-57. 2009
    ..However, nonresponsiveness is widely recognized and is related to recurrent ischemic events...
  6. ncbi Peripheral arterial disease detection, awareness, and treatment in primary care
    A T Hirsch
    Vascular Medicine Program, Minnesota Vascular Diseases Center, Mayo Mail Code 508, University of Minnesota Medical School, 420 Delaware St, SE, Minneapolis, MN 55455, USA
    JAMA 286:1317-24. 2001
    ..Peripheral arterial disease (PAD) is a manifestation of systemic atherosclerosis that is common and is associated with an increased risk of death and ischemic events, yet may be underdiagnosed in primary care practice...
  7. ncbi Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
    Jonathan Mant
    Primary Care Clinical Sciences, University of Birmingham, Birmingham, UK
    Lancet 370:493-503. 2007
    ..We assessed whether warfarin reduced risk of major stroke, arterial embolism, or other intracranial haemorrhage compared with aspirin in elderly patients...
  8. ncbi Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients
    S Schulman
    Coagulation Unit, Karolinska University Hospital, Stockholm, Sweden
    J Thromb Haemost 3:692-4. 2005
    ..The intention is to also seek approval of this definition from the regulatory authorities...
  9. pmc Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    JAMA 304:1821-30. 2010
    ..Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes...
  10. ncbi CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis
    Michael V Holmes
    Genetic Epidemiology Group, Department of Epidemiology and Public Health, University College London, 1 19 Torrington Pl, London, WC1E 6BT, United Kingdom
    JAMA 306:2704-14. 2011
    ....
  11. ncbi Clopidogrel with or without omeprazole in coronary artery disease
    Deepak L Bhatt
    Veterans AffairsBoston Healthcare System, Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 363:1909-17. 2010
    ..Recently, concerns have been raised about the potential for PPIs to blunt the efficacy of clopidogrel...
  12. ncbi Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial
    Matthew J Price
    Scripps Clinic, La Jolla, California, USA
    JAMA 305:1097-105. 2011
    ..High platelet reactivity while receiving clopidogrel has been linked to cardiovascular events after percutaneous coronary intervention (PCI), but a treatment strategy for this issue is not well defined...
  13. ncbi Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation
    Matthew J Price
    Division of Cardiovascular Diseases, Scripps Clinic, 10666 North Torrey Pines Road, Maildrop S1056, La Jolla, CA 92037, USA
    Eur Heart J 29:992-1000. 2008
    ....
  14. ncbi Prasugrel versus clopidogrel in patients with acute coronary syndromes
    Stephen D Wiviott
    Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 357:2001-15. 2007
    ..Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention...
  15. ncbi Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study
    Dimitrios Alexopoulos
    Department of Cardiology, Patras University Hospital, Rion, Patras, Greece
    J Am Coll Cardiol 60:193-9. 2012
    ..The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)...
  16. ncbi Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate
    Laurent Bonello
    Department of Cardiology, Institut National de la Santè et de la Recherche Médicale Unité Mixte de Recherche 608, Hopital Universitaire Nord, Faculte de Medecine, Marseille, France
    J Am Coll Cardiol 56:919-33. 2010
    ..This review provides a consensus opinion on the definition of high on-treatment platelet reactivity to ADP based on various methods reported in the literature and proposes how this measurement may be used in the future care of patients...
  17. ncbi Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite
    Miho Kazui
    Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co, Ltd, 1 2 58 Hiromachi, Shinagawa ku, Tokyo, 140 8710, Japan
    Drug Metab Dispos 38:92-9. 2010
    ..These results help explain the role of genetic polymorphism of CYP2C19 and also the effect of potent CYP3A inhibitors on the pharmacokinetics and pharmacodynamics of clopidogrel in humans and on clinical outcomes...
  18. ncbi Cytochrome p-450 polymorphisms and response to clopidogrel
    Jessica L Mega
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 360:354-62. 2009
    ..Clopidogrel requires transformation into an active metabolite by cytochrome P-450 (CYP) enzymes for its antiplatelet effect. The genes encoding CYP enzymes are polymorphic, with common alleles conferring reduced function...
  19. ncbi Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial
    Hisao Ogawa
    Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1 1 1 Honjo, Kumamoto City, 860 8556, Japan
    JAMA 300:2134-41. 2008
    ..Previous trials have investigated the effects of low-dose aspirin on primary prevention of cardiovascular events, but not in patients with type 2 diabetes...
  20. ncbi International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 295:180-9. 2006
    ..To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis...
  21. ncbi Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators
    E Boersma
    University Hospital Rotterdam, Rotterdam, The Netherlands
    Circulation 101:2557-67. 2000
    ..Appropriate treatment policies should include an accurate estimate of a patient's baseline risk. Risk modeling to date has been underutilized in patients with acute coronary syndromes without persistent ST-segment elevation...
  22. ncbi Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction
    Fook Hong Ng
    Department of Medicine and Geriatric, Ruttonjee Hospital, Hong Kong, China
    Am J Gastroenterol 107:389-96. 2012
    ..The objective of this study was to compare the efficacies of esomeprazole and famotidine in preventing gastrointestinal complications...
  23. ncbi Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial
    Matthew J Price
    Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA
    Circulation 124:1132-7. 2011
    ..The aim of this analysis was to examine the relationship between outcomes and OTR over the course of the trial...
  24. ncbi Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation
    Nicoline J Breet
    Department of Cardiology, St Antonius Hospital, PO Box 2500, 3435 CM Nieuwegein, The Netherlands
    JAMA 303:754-62. 2010
    ..None of the tests provided accurate prognostic information to identify patients at higher risk of bleeding following stent implantation. Trial Registration clinical trials.gov Identifier: NCT00352014 [corrected]...
  25. ncbi Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary
    Laura Mauri
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Am Heart J 160:1035-41, 1041.e1. 2010
    ..Although current clinical practice guidelines recommend 12-month treatment after drug-eluting stent placement, even longer durations may prevent thrombotic events...
  26. ncbi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
    Young Hoon Jeong
    Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
    J Am Coll Cardiol 53:1101-9. 2009
    ..The purpose of this study was to determine the impact of adjunctive cilostazol in patients with high post-treatment platelet reactivity (HPPR) undergoing coronary stenting...
  27. ncbi Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working
    Wiktor Kuliczkowski
    3rd Department of Cardiology, Silesian Center for Heart Diseases, Zabrze, Poland
    Eur Heart J 30:426-35. 2009
    ....
  28. pmc Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
    Shinya Goto
    Department of Medicine Cardiology, Tokai University School of Medicine, Isehara, Kanagawa 259 1143, Japan
    Eur Heart J 31:2601-13. 2010
    ....
  29. ncbi Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis
    Francesco Sofi
    Department of Medical and Surgical Critical Care, Thrombosis Centre, University of Florence, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
    Thromb Haemost 103:841-8. 2010
    ....
  30. pmc Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis
    George Krasopoulos
    University Health Network, Division of Cardiovascular Surgery, Toronto General Hospital
    BMJ 336:195-8. 2008
    ..To determine if there is a relation between aspirin "resistance" and clinical outcomes in patients with cardiovascular disease...
  31. ncbi Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention
    Dirk Sibbing
    Department of Cardiology, Deutsches Herzzentrum and 1 Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Eur Heart J 30:916-22. 2009
    ..The aim of this study was to assess the impact of the CYP2C19 681G>A loss-of-function polymorphism on ST following PCI performed after pre-treatment with clopidogrel...
  32. ncbi Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
    Jean Philippe Collet
    Institut de Cardiologie, INSERM 856, Universite Paris 6, hôpital Pitié Salpêtrière AP HP, Paris, France
    Lancet 373:309-17. 2009
    ..We assessed whether the CYP2C19*2 polymorphism affected long-term prognosis of patients who were chronically treated with clopidogrel...
  33. ncbi Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, 2401 W Belvedere Ave, Baltimore, MD 21215, USA
    Circulation 120:2577-85. 2009
    ..This is the first study to compare the onset and offset of platelet inhibition (IPA) with ticagrelor using the PLATO (PLATelet inhibition and patient Outcomes) trial loading dose (180 mg) with a high loading dose (600 mg) of clopidogrel...
  34. ncbi Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment
    Dominick J Angiolillo
    Division of Cardiology, University of Florida, Shands Jacksonville, 655 West 8th St, Jacksonville, FL 32209, USA
    Diabetes 54:2430-5. 2005
    ..Reduced sensitivity to antiplatelet drugs may contribute to the increased atherothombotic risk in diabetic patients...
  35. ncbi Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects
    Jean Sebastien Hulot
    INSERM U 765, Service d Hématologie Biologique A, Hopital Europeen Georges Pompidou, 20 rue Leblanc, 75908 Paris Cedex 15, France
    Blood 108:2244-7. 2006
    ....
  36. ncbi Apixaban with antiplatelet therapy after acute coronary syndrome
    John H Alexander
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27715, USA
    N Engl J Med 365:699-708. 2011
    ..Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome...
  37. ncbi Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study
    Pieter J Vlaar
    Department of Cardiology, University Medical Centre Groningen, University of Groningen, Netherlands
    Lancet 371:1915-20. 2008
    ..We aimed to investigate whether the early efficacy of thrombus aspiration seen in TAPAS translated into clinical benefit after 1 year...
  38. ncbi Platelet inhibition with cangrelor in patients undergoing PCI
    Robert A Harrington
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 361:2318-29. 2009
    ..This agent might have a role in the treatment of patients who require rapid, predictable, and profound but reversible platelet inhibition...
  39. ncbi Intravenous platelet blockade with cangrelor during PCI
    Deepak L Bhatt
    VA Boston Healthcare System and Brigham and Women s Hospital, Boston, MA 02132, USA
    N Engl J Med 361:2330-41. 2009
    ..Intravenous cangrelor, a rapid-acting, reversible adenosine diphosphate (ADP) receptor antagonist, might reduce ischemic events during percutaneous coronary intervention (PCI)...
  40. ncbi Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study
    Dominick J Angiolillo
    Division of Cardiology, University of Florida College of Medicine at Shands, Jacksonville, FL 32209, USA
    Circulation 115:708-16. 2007
    ..The aim of this pilot study was to assess the functional impact of a high maintenance dose in T2DM patients with suboptimal clopidogrel-induced antiplatelet effects...
  41. ncbi Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis
    Dirk Sibbing
    Deutsches Herzzentrum and Medizinische Klinik rechts der Isar, Technische Universitat Munchen, Munich, Germany
    J Am Coll Cardiol 53:849-56. 2009
    ..The aim of this prospective trial was to assess whether platelet reactivity to clopidogrel assessed with multiple electrode platelet aggregometry (MEA) correlates with the risk of early drug-eluting stent thrombosis (ST)...
  42. ncbi Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data
    Somjot S Brar
    Kaiser Permanente, Regional Cardiac Cath Lab, 4867 Sunset Boulevard, Los Angeles, CA 90027, USA
    J Am Coll Cardiol 58:1945-54. 2011
    ....
  43. pmc Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis
    Tim Bauer
    Department of Pharmacology, University Hospital of Cologne, D 50931 Cologne, Germany
    BMJ 343:d4588. 2011
    ..To evaluate the accumulated information from genetic association studies investigating the impact of variants of the cytochrome P450 (CYP) 2C19 genotype on the clinical efficacy of clopidogrel...
  44. ncbi Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline
    C Boustiere
    Department of Digestive Endoscopy, Hopital Saint Joseph, Marseille, France
    Endoscopy 43:445-61. 2011
    ..This guideline makes graded, evidence-based, recommendations for the management of APA for all currently performed endoscopic procedures. A short summary and two tables are included for quick reference...
  45. ncbi Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study
    Paul A Gurbel
    Sinai Center for Thrombosis Research, Cardiac Catheterization Laboratory, Baltimore, MD 21215, USA
    Circulation 121:1188-99. 2010
    ..The antiplatelet effects of the Platelet Inhibition and Patient Outcomes (PLATO) trial dose of ticagrelor in patients nonresponsive to clopidogrel and after they switch agents are unknown...
  46. pmc Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial
    Dominick J Angiolillo
    Department of Cardiology, University of Florida, Jacksonville, USA
    JAMA 307:265-74. 2012
    ..Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 to 7 days prior to surgery to minimize bleeding...
  47. ncbi Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy
    Robert F Storey
    Department of Cardiovascular Science, University of Sheffield, and NIHR Cardiovascular Biomedical Research Unit, Sheffield, United Kingdom
    J Am Coll Cardiol 56:1456-62. 2010
    ..The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes...
  48. ncbi Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
    Lars Wallentin
    Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden
    Lancet 376:1320-8. 2010
    ..CYP2C19 and ABCB1 genotypes are known to influence the effects of clopidogrel. In this substudy, we investigated the effects of these genotypes on outcomes between and within treatment groups...
  49. ncbi Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
    Christopher P Cannon
    TIMI Study Group, Brigham and Women s Hospital, Boston, MA 02115, USA
    Lancet 375:283-93. 2010
    ..We compared ticagrelor, a more potent reversible P2Y12 inhibitor with clopidogrel in such patients...
  50. ncbi Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding
    Francis K L Chan
    Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, Hong Kong, China
    N Engl J Med 352:238-44. 2005
    ..guidelines also recommend clopidrogel for patients who have major gastrointestinal intolerance of aspirin. We compared clopidogrel with aspirin plus esomeprazole for the prevention of recurrent bleeding from ulcers in high-risk patients...
  51. ncbi Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
    Eugene P McFadden
    Thoraxcenter, Erasmus University, Rotterdam, Netherlands
    Lancet 364:1519-21. 2004
    ..All cases arose soon after antiplatelet therapy was interrupted. If confirmed in systematic long-term follow-up studies, our findings have potentially serious clinical implications...
  52. pmc Platelet aggregation inhibitors from hematophagous animals
    Ivo M B Francischetti
    Vector Biology Section, Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 8132, USA
    Toxicon 56:1130-44. 2010
    ..Sialogenins have been employed as tools in biochemistry and cell biology and also display potential therapeutic applications...
  53. ncbi A risk score to predict bleeding in patients with acute coronary syndromes
    Roxana Mehran
    Columbia University Medical Center and Cardiovascular Research Foundation, New York, New York 10032, USA
    J Am Coll Cardiol 55:2556-66. 2010
    ..The aim of this study was to develop a practical risk score to predict the risk and implications of major bleeding in acute coronary syndromes (ACS)...
  54. ncbi P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use
    Lars Wallentin
    Uppsala Clinical Research Centre, University Hospital, Uppsala SE 75185, Sweden
    Eur Heart J 30:1964-77. 2009
    ..The objectives of this systematic review are to summarize the pharmacokinetics, pharmacodynamics, and pharmacogenetics of the different P2Y(12) inhibitors and to discuss the clinical implications for treatment of patients...
  55. ncbi Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease
    Robert F Storey
    Cardiovascular Medicine, University Hospital, Queen s Medical Centre, Nottingham, NG7 2UH, UK
    Platelets 13:407-13. 2002
    ..In conclusion, therapeutic administration of clopidogrel moderately inhibits platelet P2Y(12) receptor activation and substantially greater P2Y(12) receptor blockade can be achieved with AR-C69931MX...
  56. ncbi Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia
    Claire N Harrison
    Department of Haematology, University of Cambridge, and Addenbrooke s National Health Service Trust, Cambridge, United Kingdom
    N Engl J Med 353:33-45. 2005
    ..We conducted a randomized comparison of hydroxyurea with anagrelide in the treatment of essential thrombocythemia...
  57. pmc Triggers, targets and treatments for thrombosis
    Nigel Mackman
    Division of Hematology Oncology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599, USA
    Nature 451:914-8. 2008
    ..The pathogenic changes that occur in the blood vessel wall and in the blood itself resulting in thrombosis are not fully understood. Understanding these processes is crucial for developing safer and more effective antithrombotic drugs...
  58. ncbi Paraoxonase-1 is a major determinant of clopidogrel efficacy
    Heleen J Bouman
    Department of Cardiology, St Antonius Hospital Nieuwegein, Nieuwegein, The Netherlands
    Nat Med 17:110-6. 2011
    ..Thus, we identified PON1 as a key factor for the bioactivation and clinical activity of clopidogrel. These findings have therapeutic implications and may be exploited to prospectively assess the clinical efficacy of clopidogrel...
  59. ncbi Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial
    Holger Thiele
    Universität Leipzig Heart Centre, Department of Internal Medicine Cardiology, Leipzig, Germany
    Lancet 379:923-31. 2012
    ..However, the safety and efficacy of intracoronary versus standard intravenous bolus application in patients with ST-elevation myocardial infarction (STEMI) undergoing this intervention has not been tested in a large-scale clinical trial...
  60. ncbi No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting
    Dirk Sibbing
    Deutsches Herzzentrum München and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Lazarettstrasse 36, Munich, Germany
    Eur Heart J 32:1605-13. 2011
    ..The aim of this study was to assess the impact of the PON1 Q192R genotype in parallel to that of CYP2C19*2 on the antiplatelet effect of clopidogrel and the risk of ST in clopidogrel-treated patients...
  61. ncbi Thrombin-receptor antagonist vorapaxar in acute coronary syndromes
    Pierluigi Tricoci
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    N Engl J Med 366:20-33. 2012
    ..Vorapaxar is a new oral protease-activated-receptor 1 (PAR-1) antagonist that inhibits thrombin-induced platelet activation...
  62. pmc Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
    Jessica L Mega
    TIMI Study Group, Cardiovascular Division, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Lancet 376:1312-9. 2010
    ..We also assessed the effect of genotype on the pharmacodynamic and pharmacokinetic properties of these drugs in healthy individuals...
  63. pmc Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis
    Lauren C Brown
    Department of Public Health Sciences, University of Alberta, and the Institute of Health Economics, Edmonton
    CMAJ 171:1189-92. 2004
    ..e., coronary artery disease [CAD], cerebrovascular disease [CBVD] or peripheral arterial disease [PAD])...
  64. ncbi Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies
    D J Angiolillo
    Division of Cardiology, University of Florida College of Medicine, Jacksonville, Florida, USA
    Clin Pharmacol Ther 89:65-74. 2011
    ..7, 27.1, 19.0 (P < 0.0001), and 3.9% (P = 0.3319), respectively. The results suggest that a metabolic drug-drug interaction exists between clopidogrel and omeprazole but not between clopidogrel and pantoprazole...
  65. ncbi Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial
    Shamir R Mehta
    McMaster University and Population Health Research Institute, Hamilton Health Sciences, Hamilton, ON, Canada
    Lancet 376:1233-43. 2010
    ..We assessed the effect of various clopidogrel and aspirin regimens in prevention of major cardiovascular events and stent thrombosis in patients undergoing PCI...
  66. ncbi Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Bad Krozingen, Germany
    J Am Coll Cardiol 51:1925-34. 2008
    ....
  67. ncbi Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis
    Jean Sebastien Hulot
    Service de Pharmacologie, Unité de Pharmacogénétique, INSERM UMRS 956, Hopital Pitie Salpetriere, Paris, France
    J Am Coll Cardiol 56:134-43. 2010
    ....
  68. ncbi Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
    Steen Husted
    Department of Medicine and Cardiology, Arhus University Hospital, Denmark
    Eur Heart J 27:1038-47. 2006
    ..This double-blind, parallel-group study was conducted to assess the pharmacodynamics, pharmacokinetics, and safety of AZD6140, the first oral, reversible adenosine diphosphate (ADP) receptor antagonist...
  69. ncbi Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P
    David A Morrow
    TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am Heart J 158:335-341.e3. 2009
    ..Because SCH 530348 does not interfere with other pathways for hemostasis, it is possible that SCH 530348 reduces thrombosis with less increase in bleeding than do other potent antiplatelet agents...
  70. ncbi Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement
    Dirk Sibbing
    Deutsches Herzzentrum Munchen, Lazarettstrasse 36, 80636 München, Germany
    Circulation 121:512-8. 2010
    ..The aim of this study was to assess the impact of CYP2C19*17 on ADP-induced platelet aggregation, the risk of bleeding, and stent thrombosis in clopidogrel-treated patients undergoing percutaneous coronary intervention...
  71. ncbi Aspirin dose for the prevention of cardiovascular disease: a systematic review
    Charles L Campbell
    Gill Heart Institute, University of Kentucky, Lexington, USA
    JAMA 297:2018-24. 2007
    ..More than 50 million US adults take aspirin regularly for long-term prevention of cardiovascular disease, typically either 81 mg/d or 325 mg/d. Controversy remains regarding the most appropriate long-term daily dose...
  72. ncbi Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials
    Jeffrey S Berger
    Department of Medicine, Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA
    Am Heart J 162:115-24.e2. 2011
    ..The benefit of aspirin to prevent cardiovascular events in subjects without clinical cardiovascular disease relative to the increased risk of bleeding is uncertain...
  73. ncbi CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients
    Jean Sebastien Hulot
    Universite Pierre et Marie Curie Paris 6, INSERM UMR S 956, Pharmacology Department, Pitie Salpetriere University Hospital, Paris, France
    Circ Cardiovasc Interv 4:422-8. 2011
    ..We tested the effects of PON1 polymorphisms on clopidogrel pharmacokinetics and pharmacodynamics and the occurrence of cardiovascular outcomes in young post-myocardial infarction (MI) patients treated with clopidogrel...
  74. ncbi Rate of nuisance bleedings and impact on compliance to prasugrel in acute coronary syndromes
    Sebastien Armero
    Departement de Cardiologie, Hopital Universitaire Nord, Faculte de Medecine, Universite de la Mediterranee, Marseille, France
    Am J Cardiol 108:1710-3. 2011
    ..In conclusion, in the present study, minor bleedings were common during the first month after percutaneous coronary intervention and were significantly associated with prasugrel withdrawal...
  75. ncbi Platelet aggregation is dependent on platelet count in patients with coronary artery disease
    Morten Würtz
    Department of Cardiology, Aarhus University Hospital, Skejby, Denmark
    Thromb Res 129:56-61. 2012
    ..This study investigated the importance of platelet count, haematocrit, red blood cells (RBC), and white blood cells in whole blood platelet aggregometry...
  76. ncbi Meta-analysis of randomized controlled trials of intracoronary versus intravenous administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention for acute coronary syndrome
    Sayuri Friedland
    Divisions of Cardiology and Clinical Epidemiology, Jewish General Hospital, Lady Davis Institute for Medical Research, McGill University, Montreal, Canada
    Am J Cardiol 108:1244-51. 2011
    ..Data regarding mid-/long-term outcomes were limited and inconclusive. Large RCTs with longer follow-up are required to determine long-term safety and efficacy...
  77. ncbi Concomitant use of clopidogrel and proton pump inhibitors is not associated with major adverse cardiovascular events following coronary stent implantation
    M Schmidt
    Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark
    Aliment Pharmacol Ther 35:165-74. 2012
    ..Cytochrome P450 inhibition by proton pump inhibitors (PPIs) may attenuate the effectiveness of clopidogrel...
  78. ncbi Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation
    Eric L Eisenstein
    Department of Medicine, Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27710, USA
    JAMA 297:159-68. 2007
    ..Recent studies of drug-eluting intracoronary stents suggest that current antiplatelet regimens may not be sufficient to prevent late stent thrombosis...
  79. ncbi Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes
    Robert F Storey
    Cardiovascular Research Unit, University of Sheffield, Sheffield, United Kingdom
    J Am Coll Cardiol 50:1852-6. 2007
    ..clopidogRel in non-ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients...
  80. ncbi Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry
    John A Spertus
    MPH, Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111
    Circulation 113:2803-9. 2006
    ..The rate and consequences of prematurely discontinuing thienopyridine therapy after DES placement for acute myocardial infarction (MI) are unknown...
  81. ncbi Interindividual variability in the efficacy of oral antiplatelet drugs: definitions, mechanisms and clinical importance
    Morten Würtz
    Department of Cardiology, Aarhus University Hospital, Brendstrupgaardsvej 100, 8200 Aarhus, Denmark
    Curr Pharm Des 18:5344-61. 2012
    ..This article provides an integrated review of interindividual variability in the efficacy of aspirin and clopidogrel with particular emphasis on possible effect-modifying mechanisms and clinical implications...
  82. ncbi Platelet function testing in atherothrombotic disease
    Erik Lerkevang Grove
    Department of Cardiology, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, 8200 Aarhus, Denmark
    Curr Pharm Des 18:5379-91. 2012
    ....
  83. ncbi Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data
    Lisa M Askie
    Centre for Perinatal Health Services Research, University of Sydney, Sydney, Australia
    Lancet 369:1791-8. 2007
    ..Our aim was to assess the use of antiplatelet agents for the primary prevention of pre-eclampsia, and to explore which women are likely to benefit most...
  84. ncbi Antiplatelets vs anticoagulation for dissection: CADISS nonrandomized arm and meta-analysis
    Fiona Kennedy
    Stroke and Dementia Research Centre, St George s University of London, London, UK
    Neurology 79:686-9. 2012
    ....
  85. ncbi Paraoxonase-1 Q192R polymorphism and antiplatelet effects of clopidogrel in patients undergoing elective coronary stent placement
    Dietmar Trenk
    Herz Zentrum Bad Krozingen, Germany
    Circ Cardiovasc Genet 4:429-36. 2011
    ..We sought to investigate whether the PON1 Q192R gene polymorphism affects platelet reactivity in patients undergoing elective coronary stent placement...
  86. ncbi Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
    Stefan James
    Uppsala Clinical Research Center, Sweden
    Am Heart J 157:599-605. 2009
    ....
  87. ncbi Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus
    S B Mortensen
    Department of Cardiology, Aarhus University Hospital Skejby, Denmark
    Thromb Res 126:e318-22. 2010
    ..We aimed to investigate whether diabetes mellitus influenced the platelet response to aspirin in patients with CAD...
  88. ncbi The role of platelets in athero-thrombotic events
    Matthias K Freynhofer
    3rd Department of Medicine, Cardiology and Emergency Medicine, Wilhelminen Hospital, A 1160, Vienna, Austria
    Curr Pharm Des 18:5197-214. 2012
    ....
  89. ncbi Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients
    Isla M Ogilvie
    BioMedCom Consultants Inc, Montreal, Canada
    Thromb Haemost 106:34-44. 2011
    ..Antiplatelet/no therapy was associated with similar bleeding rates to OAC therapy. Increasing utilisation of anticoagulants in clinical practice could improve patient outcomes...
  90. ncbi Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping
    Dimitrios Alexopoulos
    Department of Cardiology, Patras University Hospital, Patras, Greece
    JACC Cardiovasc Interv 4:403-10. 2011
    ....
  91. pmc A cluster randomised stepped wedge trial to evaluate the effectiveness of a multifaceted information technology-based intervention in reducing high-risk prescribing of non-steroidal anti-inflammatory drugs and antiplatelets in primary medical care: the DQ
    Tobias Dreischulte
    Tayside Medicines Unit, NHS Tayside, Mackenzie Building, Kirsty Semple Way, Dundee DD2 4BF, UK
    Implement Sci 7:24. 2012
    ....
  92. ncbi Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry
    Joo Yong Hahn
    Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine
    Circ J 74:2314-21. 2010
    ..The optimal duration of dual antiplatelet therapy remains controversial...
  93. ncbi Aspirin plus clopidogrel versus aspirin alone after coronary artery bypass grafting: the clopidogrel after surgery for coronary artery disease (CASCADE) Trial
    Alexander Kulik
    Lynn Heart and Vascular Institute, University of Ottawa Heart Institute, Ontario, Canada
    Circulation 122:2680-7. 2010
    ....
  94. ncbi Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?
    M Cattaneo
    Dipartimento di Medicina, Chirurgia e Odontoiatria, Universita degli Studi di Milano, Unità di Medicina 3, Ospedale San Paolo, Milan, Italy
    J Thromb Haemost 10:327-36. 2012
    ....
  95. ncbi Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes Trial
    Michelle L O'Donoghue
    Brigham and Women s Hospital, Boston, MA 02115, USA
    Circulation 123:1843-53. 2011
    ..The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS...
  96. ncbi Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of MYocar
    Giuseppe Patti
    Department of Cardiovascular Sciences, Campus Bio Medico University, Via Alvaro del Portillo 200, Rome, Italy
    J Am Coll Cardiol 58:1592-9. 2011
    ..The purpose of this study was to compare 600- and 300-mg clopidogrel loading doses in patients with ST-segment elevation myocardial infarction (STEMI)...
  97. ncbi Thromboembolic complications of elective coil embolization of unruptured aneurysms: the effect of oral antiplatelet preparation on periprocedural thromboembolic complication
    Gyojun Hwang
    Department of Neurosurgery, Chuncheon Sacred Heart Hospital, Hallym University, Chuncheon, Korea
    Neurosurgery 67:743-8; discussion 748. 2010
    ..We retrospectively evaluated whether antiplatelet preparation lowered the thromboembolic complication rate during the perioperative period...
  98. ncbi Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliero Universitaria Sant Anna, LTTA Center, Ferrara, Italy
    J Am Coll Cardiol 57:2474-83. 2011
    ..This study sought to investigate the evolving pattern over time of on-clopidogrel platelet reactivity (PR) and its relationship with genotype and clinical outcomes after percutaneous coronary intervention...
  99. ncbi Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial
    Marie Germaine Bousser
    Hopital Lariboisiere, INSERM U, Paris Diderot University, France
    Lancet 377:2013-22. 2011
    ..We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaemic events in patients with a recent non-cardioembolic cerebral ischaemic event...
  100. ncbi The protective effects of paclitaxel on platelet aggregation through the inhibition of thromboxane A2 synthase
    Jung Jin Lee
    Department of Pharmacology, Chungnam National University College of Pharmacy, Daejeon, 305 764, Korea
    Arch Pharm Res 33:387-94. 2010
    ..This may contribute to the beneficial effects of paclitaxel on the cardiovascular system...
  101. ncbi Poor response to clopidogrel: current and future options for its management
    Gianluca Campo
    Cardiovascular Institute, Azienda Ospedaliera Universitaria S Anna, Ferrara, Italy
    J Thromb Thrombolysis 30:319-31. 2010
    ..This paper reviews the impact of clopidogrel poor responsiveness on clinical outcomes, the mechanisms leading to poor effect and the different assays to assess it. Finally, current and future options for its management is discussed...

Research Grants62

  1. Novel Antithrombotic Diadenosine Tetraphosphate Analogs
    IVAN B YANACHKOV; Fiscal Year: 2013
    ....
  2. Model of Platelet Adhesion and Thrombus Formation
    Michael R King; Fiscal Year: 2013
    ..The simulation will be first applied to the clinical investigation and diagnosis of hereditary bleeding disorders, and in the future will enable phenotype prediction of patients treated with anticoagulants such as aspirin and Plavix. ..
  3. Novel Antithrombotic Diadenosine Tetraphosphate Analogs
    IVAN B YANACHKOV; Fiscal Year: 2010
    ..The new drug will complement related drugs under development for arterial thrombosis. ..
  4. Glutamate Mediates Platelet Activation through an Ionotropic Glutamate Receptor
    Craig N Morrell; Fiscal Year: 2012
    ..The proposed study will help elucidate novel targets for the development of new therapies in the prevention and treatment of cardiovascular disease. ..
  5. Stents and Antiplatelet Drugs: Impact on Ischemia and Bleeding in the Elderly
    Samip Vasaiwala; Fiscal Year: 2011
    ....
  6. HEMORRHAGIC DISEASES
    RICHARD HERBERT ASTER; Fiscal Year: 2013
    ....
  7. Field Triage of Older Adults Who Experience Traumatic Brain Injury
    Manish N Shah; Fiscal Year: 2013
    ..Findings from this study have the potential to shift clinical practice in the prehospital setting by informing future recommendations for the identification of TBI among older adults taking anticoagulants or platelet inhibitors. ..
  8. Study of TTP: Incidence Rates and Risk Factors
    Charles Bennett; Fiscal Year: 2005
    ..Our study is unique and will advance scientific knowledge in this area. The findings of this study would facilitate health care professional for future clinical actions and public policy decisions. ..
  9. PLATELETS, PLATELET AGGREGATES & PLASMINOGEN ACTIVATION
    Joseph Loscalzo; Fiscal Year: 1991
    ..From these studies, we hope to gain insight into mechanisms by which vessel wall products facilitate dissolution of the platelet thrombi that are implicated in the pathogenesis of many vascular disorders...
  10. Development Of Prognostic Platelet RNA Biomarkers To Tailor Antiplatelet Therapy
    Deepak Voora; Fiscal Year: 2013
    ..As a consequence, an accessible, diagnostic, prognostic, and potentially actionable tool is expected to result. ..
  11. GPx-3, Vascular Oxidant Stress, and Thrombosis
    Joseph Loscalzo; Fiscal Year: 2006
    ..abstract_text> ..
  12. PLATELET AGGLUTINATION IN THROMBOTIC MICROANGIOPATHY
    ERIC LIAN; Fiscal Year: 1993
    ....
  13. PROCOAGULANT PROPERTIES OF THE SICKLE CELL MEMBRANE
    Jolyon Jesty; Fiscal Year: 1992
    ..We expect these studies to show that circulating procoagulant RSC are a significant feature in sickle-cell disease, and to delineate the causes of appearance of procoagulant activity...
  14. Diadenosine Boranotetraphosph(on)ates as Antithrombotic Drugs
    Ivan Yanachkov; Fiscal Year: 2007
    ..The new drug will complement related drugs under development for arterial thrombosis. [unreadable] [unreadable] [unreadable]..
  15. STRUCTURE/FUNCTION STUDIES OF ANTIHEMOSTATIC LIPOCALINS
    WILLIAM MONTFORT; Fiscal Year: 2003
    ..These include vasodilators, platelet aggregation inhibitors, and anticoagulants...
  16. DUKE-VA CENTER FOR CEREBROVASCULAR RESEARCH
    J Victor Nadler; Fiscal Year: 1991
    ..The projects reflect a number of experimental approaches to understanding stroke and continues to emphasize understanding the biological basis of recovery of function after stroke...
  17. PLATELET INHIBITORS: EFFECT ON CORONARY BYPASS GRAFTS
    Michael Kaye; Fiscal Year: 1980
    ....
  18. LEFT VENTRICULAR BYPASS FOR MYOCARDIAL INFARCTION
    William Pierce; Fiscal Year: 1993
    ..Our goal of this phase of the assist pump program is to complete the engineering and physiologic testing proposed by NIH and required by FDA to begin initial patient use at the completion of the proposed grant period...
  19. A NOVEL POINT-OF-CARE PLATELET FUNCTION ANALYZER
    Don Olsen; Fiscal Year: 2007
    ..The introduction of this convenient, cost-effective point-of-care platelet function analyzer would make it possible to tailor antiplatelet therapy for each individual and improve outcomes. ..
  20. Beta-receptors and cardiovascular pharmacogenomics
    Julie Johnson; Fiscal Year: 2006
    ..abstract_text> ..
  21. WARFARIN VS ASPIRIN FOR INTRACRANIAL ARTERIAL STENOSIS
    Marc Chimowitz; Fiscal Year: 2002
    ..e., greater than or equal to 6 percent per year) to justify a subsequent trial comparing intracranial angioplasty with best medical therapy in these patients. ..
  22. Nanoparticle targeting of cathepsin-L inhibitor and doxorubicin in breast cancer
    Shaker Mousa; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  23. Hypertension Pharmacogenetics
    Julie Johnson; Fiscal Year: 2006
    ..The proposed studies should add substantial new information about antihypertensive pharmacogenetics, and could influence how antihypertensive medications are prescribed in the future. ..
  24. Low-Cost Digital Imaging System for Evaluating Thrombosis
    Brian Cooley; Fiscal Year: 2008
    ..This imaging methodology may have a capacity for future adaptation to clinical thrombosis imaging. [unreadable] [unreadable] [unreadable]..
  25. Beta-adrenoceptor genetic polymorphisms and obesity
    Julie Johnson; Fiscal Year: 2002
    ..Additionally, genotyping individuals early in age may help to identify those at increased risk of obesity prior to them becoming obese so that they may take appropriate preventive measures. ..
  26. Effect of Age on Vein Graft Neointimal Formation
    Brian Cooley; Fiscal Year: 2003
    ..Furthermore, the establishment of an age-associated model of vein grafting will permit age-specific evaluation of new therapeutic avenues for inhibiting neointimal formation. ..
  27. MOLECULAR STUDY OF INSECT VECTOR ANTIHEMOSTATIC FACTORS
    Donald Champagne; Fiscal Year: 2003
    ..An understanding of the immune environment into which vector-born pathogens and parasites are transmitted may lead to novel strategies for disrupting the transmission. ..
  28. BETA-ADRENERGIC RECEPTOR POLYMORPHISMS AND HYPERTENSION
    Julie Johnson; Fiscal Year: 2003
    ..the BAR genotype significantly impacts the BP response to B-blockers could lead to improved patient outcomes, as patients could be genotyped prior to institution of B-blocker therapy, thus avoiding this therapy in those likely to respond ..
  29. Mechanisms of Pro-Thrombosis in Diabetes Mellitus
    David Schneider; Fiscal Year: 2003
    ..Further, these results will define the importance of prothrombotic potential in diabetic subjects while potentially identifying new therapeutic targets in patients with diabetes and other insulin resistant states. ..
  30. FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    Guy Young; Fiscal Year: 2007
    ..Pharmacokinetic analyses as well as safety and efficacy determinations will be made which will provide valuable information on this new anticoagulant for pediatric patients. [unreadable] [unreadable]..
  31. MALDI-TOF MS for High Throughput SNP Analysis
    ALAN SHULDINER; Fiscal Year: 2002
    ..The technology will be of great benefit to a large number of NIH-funded projects and researchers, opportunities and will greatly accelerate the pace of discovery in this post-genomic era. ..
  32. PHOSPHOLIPID SIGNALING IN MYOCARDIAL ISCHEMIC INJURY
    DIPAK DAS; Fiscal Year: 2009
    ....
  33. MYOCARDIAL PRESERVATION DURING ISCHEMIC ARREST
    DIPAK DAS; Fiscal Year: 2009
    ..Ischemic heart disease represent the major cardiovascular related problems. Straitegies to reduce ischemic injury should improve the heart health leading to the reduction of death due to heart diseases. ..
  34. BIOSYNTHESIS OF BLOOD CLOTTING PROTEINS
    Bruce Furie; Fiscal Year: 2001
    ..Detailed knowledge of these processes will improve our understanding of the biology of these proteins and has potential for improvements in hemophilia therapy. ..
  35. Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    Guy Young; Fiscal Year: 2009
    ..More modern therapies are available but have not been systematically tested in children. This study will determine whether one such medication, bivalirudin is a safer and more effective alterative. ..
  36. INTRAVITAL VIDEO-RATE CONFOCAL MICROSCOPE
    Bruce Furie; Fiscal Year: 2001
    ..The BioRad RTS2000 real-time laser confocal system, fitted to a Nikon E600FN microscope, will provide a group of investigators with instrumentation to significantly advance their fields. ..
  37. GENETICS OF DIABETES IN THE AMISH
    ALAN SHULDINER; Fiscal Year: 2009
    ..In addition, as part of the American Recovery and Reinvestment Act, this Competitive Revision will provide job opportunities and security and stimulate the economy. ..
  38. The Role of Cerebral Hemodynamics in Moya Moya Disease
    COLIN PIETER DERDEYN; Fiscal Year: 2010
    ..We will perform a post-hoc longitudinal analysis of the effect of different medical treatment regimens. Patients will return annually for follow up PET studies. ..
  39. OLD AGE LONGEVITY AND THE MARKET FOR LONG TERM CARE
    Tomas Philipson; Fiscal Year: 2001
    ..Preliminary analysis of a subpart of the data that is to be collected more fully suggest that long-tenn care output contracts with male aging as predicted. ..
  40. Novel Imaging to Predict Cardiovascular Events in Diabetes
    Zahi A Fayad; Fiscal Year: 2010
    ..It is our expectation that our data will be utilized to evaluate and improve existent treatment and develop effective new therapies to decrease the burden of atherosclerotic disease in diabetes. ..
  41. Platelet Receptor Mediated Factor X Activation
    Peter Walsh; Fiscal Year: 2005
    ..We will determine the platelet agonists, receptors, signal transduction and effector mechanisms required for binding the components of the FX-activating complex. ..
  42. Genome-wide Search for CVD Gene-Environment Interactions
    ALAN SHULDINER; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  43. Causal Models for CVD Use by Aspirin and Vitamin E in the Women's Health Study
    Nancy Cook; Fiscal Year: 2008
    ..The findings of reduced risk of CVD mortality, however, as well as effects by age, should be explored further to clarify the public health message. [unreadable] [unreadable] [unreadable]..
  44. THE EFFECT OF HMG COA REDUCTASE INHIBITORS ON CBF
    COLIN DERDEYN; Fiscal Year: 2002
    ..Positive results from these experiments would support further investigation of a potentially important mechanism of stroke protection applicable to all patients with atherosclerotic coronary and cerebrovascular disease. ..
  45. OBSERVATIONAL COHORT STUDY OF SODIUM, WEIGHT AND CVD
    Nancy Cook; Fiscal Year: 2003
    ..This cohort provides a unique resource to address the impact in a normotensive population of salt restriction and weight change on subsequent cardiovascular events. ..
  46. MECHANISMS OF ENDOTHELIAL DYSFUNCTION IN DIABETICS
    Joshua Beckman; Fiscal Year: 2003
    ..abstract_text> ..
  47. GENETIC AND CLINICAL MANIFESTATIONS OF DIABETES
    ALAN SHULDINER; Fiscal Year: 2004
    ..abstract_text> ..
  48. VERY EARLY CONSTRAINT-INDUCED MOVEMENT THERAPY:STROKE
    Alexander Dromerick; Fiscal Year: 2004
    ....
  49. Role of selectins and selectin ligands in the pathobiol*
    Bruce Furie; Fiscal Year: 2004
    ..To prove the physiologic importance of this pathway, we will attempt to rescue homozygous protein C deficient mice from fatal thrombosis by PSGL-1 deficiency. ..
  50. GENETICS OF OSTEOPOROSIS IN THE AMISH
    ALAN SHULDINER; Fiscal Year: 2004
    ..These advances will impact substantially on the quality of life of millions of older Americans with osteoporosis. ..
  51. LONG-TERM LORAZEPAM USE AND ACUTE TOXICITY IN THE AGED
    Nunzio Pomara; Fiscal Year: 2005
    ..index of brain white matter organization) contribute most strongly to the acute effects of lorazepam on cognitive/motor performance or postural sway in elderly individuals receiving long-term lorazepam treatment for GAD? ..
  52. Vascular Access in Hemodialysis Patients
    Michael Allon; Fiscal Year: 2005
    ..The applicant will assist the trainees in acquiring the conceptual skills, research experience, and motivation required to pursue a successful career in Academic Nephrology. ..
  53. MAC 1/LFA 1/P150 95 AND PMN LEUKOCYTE FUNCTION
    Christie Ballantyne; Fiscal Year: 2002
    ..3. Characterize the contribution of each CD11 integrin on the host response to common bacterial and fungal pathogens in vitro and in vivo. ..
  54. Iron and Atherosclerosis
    Subha Raman; Fiscal Year: 2006
    ..Subgroup analyses will include comparison of the presence of iron symptomatic versus asymptomatic patients and women versus age-matched men. ..
  55. Longevity Genes in Founder Populations
    ALAN SHULDINER; Fiscal Year: 2005
    ..These advances will impact substantially on the health and quality of life of older Americans. ..
  56. PHARMACOGENETICS OF PRO12ALA PPAR GAMMA 2 IN DIABETES
    ALAN SHULDINER; Fiscal Year: 2002
    ....
  57. HEMODIALYSIS VASCULAR ACCESS CLINICAL TRIALS CONSORTIUM
    Michael Allon; Fiscal Year: 2007
    ..The primary endpoint will be fistula thrombosis within 6 weeks, and the secondary endpoint will be the ability to use the fistula successfully for dialysis within 6 months. ..
  58. TRANSGENIC/KNOCKOUT ANIMALS IN MYOCARDIAL PRESERVATION
    DIPAK DAS; Fiscal Year: 2008
    ..The results of this proposed research will hopefully increase our understanding of redox regulation by Trx/Grx in the ischemic myocardium. [unreadable] [unreadable]..
  59. REFLEXES IN LEFT VENTRICULAR DYSFUNCTION
    CHULANI KAPPAGODA; Fiscal Year: 2003
    ....